Navigation Links
Some patients with incurable tumors and BRCA mutations respond to new 2-drug combination
Date:4/7/2013

WASHINGTONA novel combination of two drugs has shown anti-cancer activity in patients who had incurable solid tumors and carried a germline mutation in their BRCA genes, Dana-Farber Cancer Institute researchers are reporting at the American Association for Cancer Research annual meeting in Washington, April 6-10.

The findings (abstract LB-202) will be released at a press conference on Sunday, April 7, 2 p.m. ET, and later at an oral presentation on Tuesday, April 9, 2 p.m. ET, in Room 153, in the Washington Convention Center.

The two oral drugs, sapacitabine and seliciclib, were given sequentially in a phase 1 clinical trial that is mainly enrolling patients whose tumors lack BRCA function because of an inherited mutation.

"We have seen several responses among these patients, as well as instances of prolonged stable disease lasting more than a year," said Geoffrey Shapiro, MD, PhD, director of Dana-Farber's Early Drug Development Center (EDDC). As a result, he said that a BRCA mutation may be a potential biomarker that identifies patients who are more likely to respond to the drug combination.

Sixteen patients enrolled in the trial carried an inherited BRCA mutation. Four of these patients had partial responses a 30 percent or greater shrinkage of tumor mass including one with pancreatic, two with breast, and one with ovarian cancer. Three patients were continuing to have a partial response at the time of presentation of the data, with the longest lasting more than 78 weeks. Two additional BRCA mutation carriers, with breast and ovarian cancer, experienced stable disease for 21 and 64 weeks, respectively. Of the remaining 22 patients enrolled in the trial, six experienced stable disease for 12 weeks or more.

Sapacitabine is toxic to cancer cells by causing damage to their DNA, which, if not repaired, causes the cells to self-destruct. The BRCA protein is essential for repair of the DNA damage caused by sapacitabine, so patients with mutations that inactivate BRCA may be more sensitive to the drug's activity.

The second drug, seliciclib, is an inhibitor of cyclin-dependent kinases (CDKs), enzymes that have multiple cellular functions, including a role in DNA repair, further augmenting the effects of sapacitabine. The patients in the trial received sapacitabine twice daily for seven days, followed by seliciclib twice daily for three days. Adverse events were mild to moderate in intensity, the study found.

Shapiro and colleagues are continuing to enroll BRCA mutation carriers in the trial, and hope to determine if the mutations may serve as a biomarker for response. He said that these drugs may prove to be an important treatment alternative for patients with BRCA-deficient cancers.


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. 2-step ovarian cancer immunotherapy made from patients own tumor shows promise
2. Liver transplantation for patients with genetic liver conditions has high survival rate
3. Penn Study finds virtual colonoscopy is used appropriately, may expand screening to more patients
4. Not all patients benefit equally from hip or knee replacement: Study finds
5. Cancer Patients May Be Unintended Victims of Budget Cuts
6. WINFertility Treatment Program Expands to Central/Southern Texas. Program Makes IVF Treatment More Affordable for Patients Without Infertility Insurance Coverage.
7. Medical patients arent bargain hunters
8. Advances in molecular testing offer new hope for lung cancer patients
9. ER Workers Often Fail to Ask Suicidal Patients About Access to Guns
10. Most Doctors Dont Help Lung Cancer Patients Quit Smoking: Survey
11. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 2017 , ... The Davidson Institute for Talent Development will ... 27 at a reception in Washington D.C. The recipients received $50,000, $25,000 and ... “I am honored to be a Davidson Fellow Laureate,” said Rishab Gargeya, a ...
(Date:9/19/2017)... Brook, IL (PRWEB) , ... September 19, 2017 ... ... are significantly and positively linked to the Certified Emergency Nurse (CEN®) certification ... for Emergency Nursing (BCEN). The value of certification study, conducted by the Human ...
(Date:9/18/2017)... (PRWEB) , ... September 19, 2017 , ... ... Asia Pacific’s protein ingredient market , expected to grow at the fastest CAGR ... Sullivan sharing the ‘Global Food Protein Trends & Growth Opportunities in Asia’ – ...
(Date:9/18/2017)... ... September 18, 2017 , ... ... the finance role on the executive team adding a Chief Financial Officer following ... independent company. This expansion will support the strategic growth strategy Aegis has defined ...
(Date:9/18/2017)... Fort Lee, NJ (PRWEB) , ... September 18, 2017 , ... ... state’s history, CareOne, a New jersey based company, has launched an aid effort focused ... Irma as it battered the state over two days and left thousands homeless and ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)...   OrthoAtlanta has been named the official orthopedic ... (AFHC) for the 2018 College Football Playoff (CFP) National Championship ... Stadium in Atlanta, Georgia . OrthoAtlanta is ... campaign, participating in many activities leading up to, and including ... ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
Breaking Medicine Technology: